Pharmaceutical Companies in Japan: A Guide for Global Biotech Companies

Japan is home to a diverse range of pharmaceutical companies — from globally active companies such as Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Eisai, and Chugai Pharmaceutical, to companies with particular strengths in specific therapeutic areas, technology platforms, or the domestic Japanese market.

If you are looking for a partner in Japan for licensing, R&D, co-development, commercialization, or other forms of collaboration, the most important question is not:

"Which are the largest pharmaceutical companies in Japan?"

The more important question is:

"Which Japanese pharmaceutical companies are strategically relevant to our technology or asset?"

This guide provides an overview of the Japanese pharmaceutical industry and a practical framework for identifying companies that may be worth approaching.

Overview of the Pharmaceutical Industry in Japan

As of June 1, 2026, the Japan Pharmaceutical Manufacturers Association (JPMA) has 68 member companies representing research-based pharmaceutical companies in Japan.

The Japanese pharmaceutical landscape includes, for example:

• Large Japanese pharmaceutical companies with global operations
• Mid-sized pharmaceutical companies with a strong R&D focus
• Companies specializing in particular therapeutic areas or technologies
• Specialty pharmaceutical companies
• Japanese subsidiaries of multinational pharmaceutical companies

Understanding these differences is important for global biotech companies. The largest company by revenue is not necessarily the best partner for your business.

A smaller pharmaceutical company may have stronger scientific alignment with your technology, a track record of external collaboration in a relevant field, or an established business presence in a particular therapeutic area.

Major Japanese Pharmaceutical Companies to Know

Takeda Pharmaceutical

Takeda Pharmaceutical is one of Japan's leading global pharmaceutical companies. Its R&D activities are globally distributed, and external collaborations and partnerships form part of its research and innovation strategy. Its current R&D activities span areas including gastrointestinal and inflammatory diseases, neuroscience, oncology, and rare diseases.

For biotech companies, Takeda may be an important potential partner when there is clear alignment between their technology or asset and Takeda's current R&D priorities and technology strategy. However, approaching Takeda simply because it is a major Japanese pharmaceutical company is unlikely to be an effective partnering strategy.

The more important question is whether your asset aligns with Takeda's current R&D priorities, pipeline, and technology needs.

Astellas Pharma

Astellas Pharma is another major Japanese pharmaceutical company with global operations. Its R&D strategy incorporates a "Focus Area Approach," which explores opportunities by combining disease biology, technology platforms, and therapeutic modalities.

When evaluating a potential partnership with Astellas, global biotech companies should consider not only therapeutic-area alignment but also the company's technology interests, potential gaps or complementary opportunities within its pipeline, and existing partnerships.

Daiichi Sankyo

Daiichi Sankyo is a global, research-driven pharmaceutical company headquartered in Japan. In recent years, it has significantly increased its global presence through its oncology portfolio and activities involving antibody-drug conjugates (ADCs).

For companies developing oncology assets, platform technologies, novel modalities, or technologies related to Daiichi Sankyo's strategic areas, the company may be an important potential partner. However, therapeutic-area alignment alone may not be sufficient.

Before approaching the company, it is important to assess how your technology or asset may compete with or complement existing internal programs and external partnerships.

Eisai

Eisai is a Japanese pharmaceutical company with neurology and oncology among its key strategic areas. R&D and partnership activities in these areas continue in 2026.

Biotech companies working in neurological diseases, including Alzheimer's disease, or oncology may find potential strategic alignment. Depending on the specific program, companies developing related biomarkers, diagnostics, or technologies that support drug discovery and development may also find relevant opportunities.

Chugai Pharmaceutical

Chugai Pharmaceutical is one of Japan's leading research-driven pharmaceutical companies and a member of the Roche Group. At the same time, Chugai remains listed on the Tokyo Stock Exchange and maintains its own management structure.

When considering a potential collaboration with Chugai, it is therefore important to understand not only Chugai's own R&D strategy but also its strategic alliance with Roche and its position within the broader Roche Group.

Look Beyond the Largest Pharmaceutical Companies

Global biotech companies looking for potential partners in Japan do not need to limit their search to the largest pharmaceutical companies. Depending on the technology and therapeutic area, companies such as the following may also be important candidates.

• Ono Pharmaceutical — Focuses its R&D activities on areas including oncology, immunology and inflammation, and neurology, while also utilizing open innovation.
• Otsuka Pharmaceutical — Operates globally across multiple therapeutic areas, including psychiatry and neurology, and may be a relevant potential partner depending on the technology or asset.
• Shionogi — Widely known for its work in infectious diseases, while also conducting R&D and external collaborations in other areas.
• Kyowa Kirin — A global research-driven biopharmaceutical company with activities in specialty areas, including rare diseases.
• Sumitomo Pharma — Currently focuses on psychiatry and neurology as well as oncology, while also pursuing R&D in areas including regenerative medicine and cell therapy.
• Taiho Pharmaceutical — Conducts R&D and business activities primarily in oncology and may be a relevant candidate for companies working in related areas.
• Nippon Shinyaku — Conducts R&D and commercial activities in specialty pharmaceuticals and areas including rare diseases.
• Santen Pharmaceutical — Operates globally with a strong focus on ophthalmology and may be an important potential partner for companies developing ophthalmic therapeutics or related technologies.
• JCR Pharmaceuticals — Active in biopharmaceuticals, rare diseases, and drug delivery technologies, and may be relevant to companies working in related areas.

The key point is that the Japanese companies worth prioritizing can look very different for an oncology company, a CNS company, a rare disease company, a diagnostics company, or an AI drug discovery company.

How to Identify the Right Japanese Pharma Partners

Rather than starting with company size, it is more useful to evaluate potential partners across several dimensions.

1. Therapeutic Area Fit

Start by examining the therapeutic areas the company is currently prioritizing. Does it conduct R&D or commercial activities in the same therapeutic area as your company?

More importantly, is that area still strategically important, with continued R&D activity and investment?

2. Pipeline Fit

Review the company's current pipeline. For example, look at:

• Existing programs in relevant indications
• Areas where your asset could complement the pipeline
• Development stages of relevant programs
• Potentially competing internal programs
• Recently discontinued or changed programs
• Expansion into adjacent indications

Rather than relying on company size alone, analyzing the actual pipeline can provide more useful signals about potential strategic fit.

3. Modality and Technology Fit

Two pharmaceutical companies interested in the same therapeutic area may have very different technology strategies. Depending on your technology, examine how the company is conducting R&D or partnering in areas such as:

• Small molecules
• Antibodies
• ADCs
• Cell and gene therapies
• RNA therapeutics
• Targeted protein degradation
• Biomarkers and diagnostics
• AI-enabled drug discovery
• Drug delivery technologies

Even when therapeutic-area alignment is strong, partnering priority may be lower if the company's modality or technology strategy does not align with your platform or asset.

4. Recent Partnerships and Transactions

Past partnering activity is one useful signal for understanding a company's interest in external innovation. Review recent:

• Licensing agreements
• M&A transactions
• Research collaborations
• Option agreements
• Co-development agreements
• Academic collaborations
• Investments

This can help answer an important question:

"Is this company actually partnering externally in areas relevant to us?"

Past transactions alone, however, cannot predict future partnering appetite. They should be considered alongside the company's current corporate strategy, pipeline, and R&D needs.

5. Japan-Specific Strategic Fit

Finally, ask why partnering with this company in Japan would make strategic sense. For example:

• Does the company have an established commercial presence in the relevant therapeutic area in Japan?
• Is there an important patient population or unmet medical need in Japan?
• Are Japanese KOLs or research groups particularly relevant?
• Can the partner provide capabilities your company currently lacks?
• Is there a strategic reason to enter the Japanese market now?

This helps prevent partner research from becoming little more than a company-list-building exercise.

You Don't Need a List of 100 Companies

One approach that can be less useful in Japan market research is starting by building the longest possible list of pharmaceutical companies. For many emerging biotech companies, maximizing the number of companies on the list is not the goal.

A more practical process is:

Market Landscape → Scientific Fit → Strategic Fit → Partnering Evidence → Prioritization → Outreach

You may initially review dozens of Japanese companies. After a more detailed assessment, however, the number of companies worth prioritizing for deeper research may narrow to around 10–20 in some cases.

From there, an even smaller group can be identified as the highest-priority targets. Such a shortlist can be far more useful for actual partnering activities than an Excel spreadsheet containing every pharmaceutical company in Japan.

From a Company List to a Japan Partnering Strategy

Japan has many pharmaceutical companies that could potentially become partners for global biotech companies. Finding the companies, however, is only the starting point.

The more important questions are:

Which companies have the strongest scientific fit with our technology or asset? Which companies have a strategic reason to talk to us? Which companies are actively engaging in external innovation in relevant areas? And who should we approach first?

For global biotech companies, the objective of partner research in Japan is not to build the longest possible list of pharmaceutical companies. The goal is to identify a focused group of companies where both sides have a clear reason to start a conversation.